



Agilent

Trusted Answers



Ki-67 IHC MIB-1 pharmDx (Dako Omnis)

A More Complete Picture.

Ki-67 IHC MIB-1 pharmDx (Dako Omnis) is now available in the U.S. as an aid in identifying patients with early breast cancer at high risk of disease recurrence for whom adjuvant treatment with Verzenio® (abemaciclib) in combination with endocrine therapy is being considered.

